SCHEDULE: Nantahala Capital Discloses 2.8% Stake in X4 Pharma

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 2.80% beneficial ownership stake in X4 Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively hold beneficial ownership of 2,449,468 shares of X4 Pharmaceuticals, Inc. Common Stock.
• This ownership represents 2.80% of the total outstanding shares of X4 Pharmaceuticals, Inc. as of December 31, 2025.
• The Reporting Persons share both voting power and dispositive power over all 2,449,468 shares.
• Nantahala Capital Management, LLC is identified as an investment adviser, while Messrs. Harkey and Mack are control persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under §§ 240.14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal. While the stake is passive and below 5%, the disclosure of an institutional investor holding shares suggests a degree of confidence in X4 Pharmaceuticals, Inc.'s value proposition.

Positives

• An institutional investment adviser, Nantahala Capital Management, LLC, holds a significant stake, which can be interpreted as a vote of confidence in X4 Pharmaceuticals, Inc.'s long-term prospects.
• The filing explicitly states the investment is in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, long-term investment approach.

Negatives

• The 2.80% stake is below the 5% threshold typically associated with more influential or activist positions, limiting the immediate impact of this ownership disclosure.
• The passive nature of the investment, as certified by the Reporting Persons, indicates they do not intend to actively push for strategic or operational changes at X4 Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investors like Nantahala Capital Management frequently take passive stakes in biotechnology and pharmaceutical companies, signaling confidence in the company's pipeline or market position without seeking active control. A 2.8% stake is a common size for such passive investments, reflecting a belief in the company's underlying value.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor, common across the industry for stakes below 5% that are not intended for control.
• Compared to activist investors who might acquire larger stakes (e.g., >5-10%) and publicly advocate for changes (e.g., Starboard Value's campaigns), Nantahala's position is explicitly passive, aligning with typical investment adviser roles.

Stakeholder Impact

• Shareholders may view the presence of an institutional investor as a positive indicator of the company's investment appeal, potentially bolstering investor confidence.
• The passive nature of the investment suggests no immediate impact on company strategy or management, maintaining the current operational trajectory.

Key Dates

Recommendation

This Schedule 13G filing primarily provides information on beneficial ownership and does not contain sufficient financial or operational details to warrant a strong buy or sell recommendation. The disclosure of a passive 2.80% stake by an investment adviser is a data point that suggests institutional interest but does not fundamentally alter the investment thesis for X4 Pharmaceuticals, Inc. without further context on the company's performance or strategic direction. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while awaiting more comprehensive financial updates.

Keywords

X4 Pharmaceuticals, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals